Avidity Biosciences

10975 N. Torrey Pines Road
Suite 150
La Jolla
California
92037
United States

Tel: 858-401-7900

Website: http://www.aviditybiosciences.com/

About Avidity Biosciences

Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.

Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.

We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.

82 articles with Avidity Biosciences

Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer

4/5/2022

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.
Avidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual Meeting

3/29/2022

Avidity Biosciences, Inc. today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington , April 2-7, 2022.
Avidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific Conference

3/7/2022

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference.
Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights

3/1/2022

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress.
Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

2/23/2022

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer.
Five Top CEOs to Watch in 2022

2/23/2022

Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
Avidity Biosciences to Participate in Upcoming Investor Conferences - Feb 11, 2022

2/11/2022

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.
Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event

12/9/2021

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast investor and analyst day event titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.
Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

11/9/2021

Avidity Biosciences, Inc. (Nasdaq: RNA), today reported financial results for the third quarter and nine months ended September 30, 2021 and highlighted recent corporate progress.
Clinical Catch-Up: November 1-5

11/8/2021

The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

11/4/2021

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC.
Avidity Biosciences to Participate in Upcoming Investor Conferences - Nov 02, 2021

11/2/2021

Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

10/18/2021

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program, AOC 1001, for the treatment of myotonic dystrophy type 1 (DM1).
Avidity Biosciences to Participate in Upcoming Investor Conferences - Aug 31, 2021

8/31/2021

Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences
European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

8/24/2021

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the European Commission has granted orphan designation for AOC 1001.
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

8/16/2021

Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes to Validate Evaluations Plus (MOVE+) Study.
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

8/9/2021

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted recent corporate progress.
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

8/3/2021

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $18.00 per share.
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock - Aug 02, 2021

8/2/2021

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)

8/2/2021

Avidity Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).